Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus VERILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus VERILOID.
AFEDITAB CR vs VERILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
VERILOID is a synthetic alkaloid that acts as a ganglionic blocker, inhibiting nicotinic acetylcholine receptors at autonomic ganglia, leading to reduced sympathetic and parasympathetic outflow. This results in vasodilation and decreased peripheral vascular resistance, lowering blood pressure.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Intravenous: 0.1-0.5 mg/kg bolus, followed by 0.5-2 mcg/kg/min continuous infusion. Oral: 20-80 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Terminal elimination half-life is 3-5 hours, clinically relevant for dose scheduling to maintain steady-state levels.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal excretion accounts for approximately 60% as unchanged drug; hepatic metabolism contributes 30% with biliary-fecal elimination of metabolites, totaling ~10% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker